Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

10.03
+0.36003.72%
Post-market: 10.030.00000.00%19:56 EST
Volume:1.15M
Turnover:11.45M
Market Cap:991.45M
PE:-12.30
High:10.05
Open:9.87
Low:9.70
Close:9.67
52wk High:18.90
52wk Low:6.66
Shares:98.85M
Float Shares:55.27M
Volume Ratio:0.87
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8154
EPS(LYR):0.0800
ROE:-45.92%
ROA:-19.22%
PB:6.71
PE(LYR):125.38

Loading ...

EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children

Reuters
·
Feb 02

Eurneffy® 1 Mg (Adrenaline Nasal Spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, Including Anaphylaxis in Children Weighing ≥15 Kg to <30 Kg

THOMSON REUTERS
·
Feb 02

EU Regulators Recommend Approval of ALK-Abelló's EURneffy 1 mg Nasal Spray for Pediatric Anaphylaxis

Reuters
·
Jan 29

ARS Pharmaceuticals announces California eligible for neffyinSchools program

TIPRANKS
·
Jan 21

ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk

Dow Jones
·
Jan 13

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

Benzinga_recent_news
·
Jan 10

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

TIPRANKS
·
Jan 09

ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy

Simply Wall St.
·
Dec 30, 2025

China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product

Reuters
·
Dec 29, 2025

ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026

THOMSON REUTERS
·
Dec 29, 2025

ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones

THOMSON REUTERS
·
Dec 29, 2025

Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)

THOMSON REUTERS
·
Dec 29, 2025

ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares

Reuters
·
Nov 15, 2025

ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28

THOMSON REUTERS
·
Nov 14, 2025

Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses

Stock Track
·
Nov 10, 2025

Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth

Stock Track
·
Nov 10, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss

MT Newswires Live
·
Nov 10, 2025

ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate

Benzinga
·
Nov 10, 2025

ARS Pharmaceuticals Q3 Net Income USD -51.151 Million

THOMSON REUTERS
·
Nov 10, 2025

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)

THOMSON REUTERS
·
Nov 10, 2025